Published in Surgery Litigation and Law Weekly, November 20th, 2009
"The selection of a world-class CRO is an important milestone in our product development process and it underscores our commitment to advance ANAVEX 2-73 through Phase I clinical trials," said Dr. Herve de Kergrohen, CEO of ANAVEX. "We are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly